1. Management and Key Leader Group

Management and Key Leader Group

Introducing Management and
Key Leader Group of Helixmith.





Sunyoung KIM, D. Phil
CEO, Representative Director

  • 1996~present

    CEO of Helixmith

  • 2014~2016

    Director of National Research Council of Science & Technology (NST)

  • 2013~2015

    President of Seoul National University Bio-MAX Institute

  • 2010~2011

    Investment manager in fusion new industry sector of R&D strategy planning group, ministry of knowledge economy

  • 2006~2008

    The 1st and 2nd Chairman of the Korean Society of Gene Therapy

  • 1992~2018

    Professor, Biological Sciences, Seoul National University

  • 1990~1992

    Assistant Professor, Harvard Medical School

  • 1987~1989

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1986

    PhD, Molecular Genetics, the University of Oxford

  • 1984

    Master, Microbiology/Molecular Genetics, Harvard University

  • 1982

    Master, Bioengineering, MIT

  • 1978

    BS, Microbiology, Seoul National University

Sunyoung KIM D. Phil

Seungshin Yu, Ph.D.
CTO, Representative Director

  • 2020~present

    CTO of Helixmith

  • 2008~2019

    Former Director of Bio Headquarter, President of Research Institute

  • 2005~2008

    Department Head, Takara Bio Research Institute

  • 1995~1997

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1984~1995

    BS, Microbiology, Seoul National University, Master/Ph.D, Virology at Seoul National University

Seungshin Yu CTO

Key Leader Group

  • PresidentWon Ho Park

  • Process Development & Manufacturing TechnologiesKyungdong Bae

  • Clinical Development
    & Operation
    Youngjoo Park

  • Strategic Planning DivisionJehee Suh

  • Clinical DevelopmentWilliam K. Schmidt

  • Head of MedicalWilliam O. Frank

  • Regulatory AffairsThu Doan

  • Quality AssuranceJose Zapata

Key Leader Group

PresidentWon Ho Park

  • INFAC(Mexico) Overseas factory, Executive director
  • INFAC Sales Headquarters, Executive director
  • Hyundai Steel Raw material inspection view, Head of department
  • Hyundai Motor’s Group Audit Planning Team
  • Hyundai Motor’s Procurement Division
  • BS, Department of Mechanical Engineering, Ajou University

Key Leader Group

Process Development & Manufacturing TechnologiesKyungdong Bae

  • Director & Co-chairman, Korean Society for Biotechnology and Bioengineering
  • Member of Expert Committee at Advanced Therapy and Expert Panel at Plasmid DNA, US Pharmacopeia (2020~2025 cycle)
  • Director & Head of Vaccine Process and Analytical Development, Janssen Vaccine Korea
  • Adjunct professor, Department of Bioengineering, Graduate School of Inha University
  • BS/MA/PhD, Department of Chemical and Biological Engineering, Inha University

Key Leader Group

Clinical Development & OperationYoungjoo Park

  • Senior Director for External Cooperation and Business Development, Korea National Enterprise for Clinical Trials, Affiliation of Ministry of Health and Welfare
  • Sanofi, Head of Clinical Study Unit, R&D
  • MSD, Senior Manager for biostatistics, data management, pharmacovigilance, and medical writing
  • Master of Public Health, Ph.D. in Epidemiology, Seoul National University
  • BS, Life Science, Ewha Womans University

Key Leader Group

Strategic Planning DivisionJehee Suh

  • CAR-T cell therapy subsidiary of Helixmith
  • Former Head of Global Business Strategy and Business Development
  • Partner at McKinsey & Company (Pharmaceuticals & Medical Products)
  • Marketing, Novartis Korea
  • Wharton MBA, major in Healthcare Management
  • BS, Biology, Seoul National University

Key Leader Group

Clinical DevelopmentWilliam K.Schmidt

  • President, North Star Consulting
  • Chief Medical Officer, Ensysce Bioscience
  • Vice President of Clinical Development, EicOsis
  • Postdoctoral training, Boston University School of Medicine
  • PhD in Pharmacology, UC San Francisco

Key Leader Group

Head of MedicalWilliam O. Frank

  • Vice President, Retrophin Inc.
  • Vice President, Vital Therapies Inc.
  • Senior Medical Director and Vice President, Santarus Inc.
  • Senior Medical Director, Novartis
  • Director, Clinical Research & Development, Sandoz
  • Group Director, Clinical Development & Medical Affairs, Smith-Kline Beecham Pharmaceutical Corporation
  • MD, Temple University
  • BS in Chemistry and Biological Sciences, University of Pittsburgh

Key Leader Group

Regulatory AffairsThu Doan

  • Director, Regulatory Affairs, Kite Pharma
  • Director, Regulatory Affairs, Intercept Pharmaceuticals
  • Senior Manager, Regulatory Affairs, Allergan Pharmaceuticals
  • Manager, Regulatory Affairs, Biogen Idec Pharmaceuticals
  • PharmD, University of Missouri
  • BS in Biology, University of California
  • California Registered Pharmacist (RPh)

Key Leader Group

Quality AssuranceJose Zapata

  • Sr. Director (QA), Histogen
  • Director Quality Assurance, Quality System, Conatus Pharma
  • Director (QA), Peregrine Pharmaceuticals Inc.
  • Director (QA-Renal division), OPKO (Formally Cytochroma)
  • Associate Director (QA), Immtech Pharmaceutical
  • Director (QA & Regulatory Affairs), Resource Optimization Innovation
  • Director (QA), Triad Pharmaceuticals
  • Quality Assurance Director (Fluid Air), PharmaPro Services
  • Manager (QA), Opportunity Medical
  • Quality & Regulatory (M.S.), Temple University – Lewis Katz School of Medicine
  • Biological Science (B.S.), DePaul University